Amgen’s most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $165.00 short call and a strike $175.00 long call offers a potential 5.6% return on risk over the next 27 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $165.00 by expiration. The full premium credit of $0.53 would be kept by the premium seller. The risk of $9.47 would be incurred if the stock rose above the $175.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is at 26.16 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Amgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab
Fri, 19 May 2017 14:20:02 +0000
Amgen Inc. (AMGN) recently announced the submission of a biologics license application (BLA) to the FDA for its pipeline candidate erenumab (AMG 334) for the prevention of migraine.
Amgen, Inc. : AMGN-US: Dividend Analysis : May 17th, 2017 (record date) : By the numbers : May 18, 2017
Thu, 18 May 2017 15:49:15 +0000
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Amgen, Inc. with the following peers – Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, Celgene Corporation, Gilead Sciences, Inc., AbbVie, Inc., Biogen Inc., Alexion Pharmaceuticals, Inc., Abbott Laboratories and Johnson & Johnson (PFE-US, BMY-US, GSK-US, CELG-US, GILD-US, ABBV-US, BIIB-US, ALXN-US, ABT-US and JNJ-US). … Read more
AbbVie Down on Humira Patent Loss: Is More Damage in Store?
Thu, 18 May 2017 13:23:01 +0000
AbbVie Inc.'s (ABBV) shares declined more than 2% on Wednesday after it lost a lawsuit related to a patent protecting its key rheumatoid arthritis drug, Humira to small biotech Coherus BioSciences, Inc. (CHRS),
Amgen Submits Biologics License Application To The FDA For Erenumab
Thu, 18 May 2017 13:00:00 +0000
THOUSAND OAKS, Calif., May 18, 2017 /PRNewswire/ — Amgen (AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for erenumab to prevent migraine. Erenumab is specifically designed to prevent migraine by blocking the Calcitonin Gene-Related Peptide (CGRP) receptor. This BLA includes data from pivotal studies in patients with episodic and chronic migraine.
AbbVie Loses Key Humira Patent In Battle With Small-Cap Biotech
Wed, 17 May 2017 21:02:07 +0000
Coherus stock rocketed to a two-month high Wednesday after a U.S. board tossed out a key patent protecting AbbVie's most important drug, Humira.
Also on Market Tamer…
Follow Us on Facebook